Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
07/21/2023 8-K Quarterly results
07/20/2023 8-K Quarterly results
05/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/25/2023 8-K Quarterly results
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’ s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’ s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal Models"
12/23/2022 8-K Quarterly results
12/06/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
10/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP"
10/11/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/24/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
03/23/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’ s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy"
10/13/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute and Oncode Institute to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment"
09/20/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "TroyGould PC 1801 Century Park East, Suite 1600 Los Angeles, California 90067",
"SALES AGREEMENT"
07/09/2021 8-K Quarterly results
06/03/2021 8-K Quarterly results
05/14/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/02/2021 8-K Quarterly results
01/22/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Clinical Research Support Agreement with City of Hope",
"Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’ s Lead Compound LB-100 to Treat Small Cell Lung Cancer"
11/27/2020 8-K Quarterly results
08/18/2020 8-K Quarterly results
07/17/2020 8-K Quarterly results
07/17/2020 8-K Quarterly results
08/06/2019 8-K Quarterly results
11/07/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Approves Lixte Biotechnology’ s IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center"
08/23/2018 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Clinical Trial Research Agreement1",
"Exclusive License Agreement",
"Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate a Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome EAST SETAUKET, NY — - Lixte Biotechnology Holdings, Inc . announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement with Moffitt Cancer Center to conduct a Phase 1b/2 study of the safety and therapeutic benefit of Lixte’ s lead clinical compound, LB-100, in patients with myelodysplastic syndrome . The trial will enter low and intermediate-1 risk MDS patients, including those with del MDS who have failed or are intolerant of standard treatment. Dr. John S. Kovach, founder and CEO of Lixte, said, “Certain cancers posse..."
08/09/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Yun Yen, MD, PhD and Winson Ho, MD Join Lixte Biotechnology’ s Board of Directors"
04/10/2017 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy